Familial restrictive cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Familial restrictive cardiomyopathy is an inherited disease in which one or more members of a family develop severely limited ventricular filling, elevated diastolic pressures and atrial dilation without an infiltrative or acquired cause sufficient to explain the picture. In most molecularly resolved families, inheritance is autosomal dominant, but de novo variants and rare recessive forms broaden the spectrum. The familial definition derives from integration of pedigree, phenotype and genetics, not merely from dyspnea occurring in several relatives.

The same genetic defect does not necessarily produce the same morphology in all carriers. A parent may be classified as having hypertrophic cardiomyopathy, a child as restrictive cardiomyopathy and another relative may show only enlarged atria or conduction disturbances; some desminopathies add weakness and contractures. This variable expressivity reflects age, variant type, genetic background and modifiers that remain incompletely understood and makes screening limited to the proband's identical phenotype unsafe.

A pathogenic or likely pathogenic variant makes it possible to identify relatives who require surveillance and, as a rule, to release noncarriers from the variant-specific pathway. A variant of uncertain significance does not have the same power: it does not confirm causality, should not guide predictive testing and does not justify devices or restrictions. Interpretive discipline is particularly important in rare diseases, in which a private variant and a small pedigree can create an apparent but false association.

Genetic diagnosis does not remove the need to exclude acquired causes. A carrier may also have hypertension, ischemia, age-related amyloidosis or constrictive pericarditis, and a gammopathy does not become irrelevant because a variant is present. The principle of competing causes protects against the error of attributing every sign to DNA and keeps specific therapeutic options open.

Sarcomere, cytoskeleton and intermediate filaments

TNNI3 encodes cardiac troponin I, the inhibitory component of the troponin complex that regulates actin access to myosin according to calcium concentration. Missense variants in functional regions may increase calcium sensitivity or impair inhibition, prolonging myofilament activation during diastole. The result is incomplete sarcomeric relaxation that can produce severe restriction with modest wall thickness and initially preserved systolic contractility.

Observations by Mogensen and colleagues demonstrated TNNI3 variants in cases previously considered idiopathic and in families with restrictive and hypertrophic phenotypes. Some de novo variants are associated with severe childhood onset, whereas others segregate in families with variable manifestations. Not every TNNI3 variant is restrictive and many cause HCM; variant specificity therefore matters more than a generic association of the gene with cardiomyopathy.

MYH7, TNNT2, ACTC1, MYL2 and MYL3 encode other sarcomeric components described across the RCM spectrum. A cohort published in 2025 identified MYH7 as an important cause in a Chinese RCM population and an association with transplantation, but estimates depend strongly on selection and definition. Sarcomeric sharing with HCM and DCM explains overlap without authorizing every cardiomyopathy gene to be used as a validated RCM gene.

FLNC encodes filamin C, a Z-disc protein that links contractile structures, membrane and signaling systems. Specific missense variants have been demonstrated in families with restriction, protein aggregates and variable myopathy, whereas truncating FLNC variants are better known for dilated or arrhythmogenic phenotypes. The allelic mechanism is essential: different variants in the same gene may act through loss of function, misfolding or aggregation and generate different risks.

DES encodes desmin, the intermediate filament that links the Z disc, junctions, nucleus and organelles. Dominant variants and rare biallelic variants may produce myofibrillar myopathy, restrictive or dilated cardiomyopathy, atrioventricular block and arrhythmias. Cardiac disease may precede muscle weakness by years, so a normal neurologic examination does not exclude a desminopathy. The desmin network connects mechanics and conduction and explains why early pacemaker implantation is an important genealogic clue.

FHL1, BAG3, CRYAB and other genes have been reported in families or syndromes with restriction, but the level of evidence, mode of inheritance and phenotypic specificity are not uniform. Indiscriminate inclusion in panels increases the number of uncertain results. Gene-disease validity should be updated and declared by the laboratory, while segregation and functional data should be weighted without overestimating a single publication.

Building the pedigree and formulating the test

The pedigree includes at least three generations and records current age or age at death, heart failure, arrhythmias, syncope, stroke, pacemaker, ICD, transplantation, myopathy and apparently different diagnoses. Sudden deaths, drownings or unexplained accidents merit documentary verification when possible. Phenotypic genealogy is not an ornamental drawing: it selects the most informative relatives, suggests inheritance and changes the probability that a variant is causal.

The proband should receive counseling that clarifies possible positive, negative and uncertain results, implications for relatives and predictive limitations. The panel includes genes with an established relationship to the phenotype and may be broadened when neuromuscular or syndromic signs provide a specific indication. Informed genetic consent includes the possibility of unexpected findings, privacy, insurance according to local law and the right of relatives to choose whether to know the result.

Classification follows ACMG/AMP criteria adapted to cardiomyopathies, integrating population frequency, variant type, functional region, segregation, experimental data and independent observations. Absence from databases does not automatically make a private variant pathogenic, and an in silico algorithm does not replace clinical evidence. The strength of evidence must be explicit because it determines whether the result can be used within the family.

A pathogenic variant identified in the proband is sought by targeted testing in relatives. Carriers enter surveillance; noncarriers can generally stop screening for that variant unless a second clinically plausible cause exists. If the proband's test is negative, clinical screening of relatives remains necessary. Cascade testing is informative only when the initial variant has been classified with sufficient certainty.

Trio analysis in a child compares the child and parents and can demonstrate a de novo variant, strengthening interpretation when gene and phenotype are consistent. A presumed de novo event requires confirmation of biologic parentage and consideration of germline mosaicism, which leaves a small reproductive risk for the parents. The family structure of testing can produce more information than a larger panel analyzed without relationships.

From genotype to clinical phenotype

Assessment of a carrier includes symptoms, examination, ECG, echocardiography and, according to age and gene, Holter monitoring and magnetic resonance. Small reductions in e' velocities, atrial enlargement, conduction abnormalities or fibrosis may precede recognizable heart failure. No single borderline finding demonstrates penetrance, but their convergence over time builds a more reliable early phenotype.

With sarcomeric genes, wall thickness and distribution of hypertrophy should be measured without excluding restriction when the wall exceeds a threshold. A mixed hypertrophic-restrictive phenotype may be particularly severe in children and require early transplant evaluation. Classification by dominance describes the predominant manifestation but should not erase other relevant components.

With FLNC and DES, investigation includes arrhythmias, conduction and neuromuscular signs. Normal creatine kinase does not exclude myopathy and mild symptoms may emerge only with targeted examination, electromyography or muscle imaging when indicated. Neuropathy does not automatically belong to the gene and requires a differential diagnosis. Extracardiac phenotyping strengthens causality and anticipates complications that echocardiography alone does not reveal.

Penetrance is age dependent and may be incomplete; an older nearly normal parent does not negate pathogenicity if other strong evidence exists, but it lowers penetrance estimates. Sex, pregnancy, comorbidities and activity may also modify expression, with RCM-specific data still limited. The probability of disease is not the same as the 50% probability of transmitting an autosomal dominant variant.

The absence of phenotype in a child carrier does not predict future age at onset or severity. Families should receive balanced information, avoiding both false reassurance and the idea of an inevitable destiny. Predictive counseling distinguishes genetic risk, clinical penetrance and event risk, three concepts often confused but crucial for school, sport and psychological well-being.

Surveillance of carriers and unresolved families

Follow-up intervals are adapted to age at onset in the family, the gene, previous findings and symptoms. In general, surveillance is closer during growth and adolescence or when the pedigree includes early-onset disease. A new symptom advances the evaluation regardless of the calendar. Flexible screening is safer than a universal interval applied to biologically different families.

ECG and echocardiography form the minimum core, while Holter monitoring and magnetic resonance increase sensitivity for conduction disease, arrhythmias and tissue abnormalities. The choice should not produce repeated radiation or sedation without benefit, especially in young children. The burden of surveillance is part of the decision: appropriate, comparable tests are preferable to very frequent but poorly interpretable checks.

If the proband has no informative variant, first-degree relatives are followed clinically because a negative test does not reduce risk to population level. Recognition of a second affected relative may strengthen the familial diagnosis and make renewed genetic analysis useful. The family as a cohort generates longitudinal evidence and can transform an initially unresolved result.

Pregnancy and reproductive planning require counseling before conception. For an autosomal dominant variant, the transmission risk in each pregnancy is 50%, but severity and penetrance cannot be predicted precisely; prenatal and preimplantation diagnosis are options that depend on law and preferences. Reproductive autonomy requires nondirective information and sufficient time, not a standard recommendation.

Physical activity is advised according to phenotype, arrhythmias and hemodynamic response. There is no evidence requiring every asymptomatic RCM carrier to follow the same restriction used for specific arrhythmogenic cardiomyopathies, but intense exertion may be poorly tolerated in the presence of fixed output. Individualized prescription avoids unjustified sedentary behavior and recognizes the limits of established restrictive physiology.

Treatment, risk and advanced failure

At present there is no approved gene therapy that corrects TNNI3, FLNC, MYH7 or DES in familial RCM. Treatment controls congestion, rhythm, thromboembolism and conduction complications, while research into causal therapy remains experimental. Knowledge of the gene improves family precision and attention to associated manifestations, but should not be presented as availability of a molecular cure.

Diuretics are titrated cautiously and heart-failure therapy is adapted to blood pressure and systolic function. In a desminopathy with block, pacing may be necessary before severe congestion appears; in a phenotype with ventricular arrhythmias, an ICD is discussed according to history, scar and prognosis. Gene-informed management adds information to the decision without replacing clinical criteria and available evidence.

Risk of death may result from progressive failure, arrhythmia, block or thromboembolism and varies among genes and individuals. An ICD prevents some tachyarrhythmic mechanisms but not terminal low output; a pacemaker corrects bradycardia but not myocardial stiffness. Mechanism-treatment matching should be discussed clearly to avoid unrealistic expectations of devices.

Referral for transplantation is brought forward in the presence of childhood onset, pulmonary hypertension, rapidly increasing symptoms, hospitalizations or organ dysfunction. Genetic diagnosis can clarify extracardiac risk and candidacy, especially in systemic myopathies, but many isolated forms achieve good results after transplantation. Timeliness of referral remains the most important modifiable factor when cardiomyopathy progresses despite therapy.

The family continues to be followed even after transplantation of the proband. The transplanted heart corrects the recipient's cardiac manifestation but does not change the germline variant or relatives' risk; muscle manifestations may also progress according to the gene. Genetic continuity beyond transplantation maintains screening, reproductive counseling and information updates for the entire family.

Gene-specific correlations and their limits

RCM-associated TNNI3 variants tend to be missense and to alter regions regulating interaction with actin, troponin C or T. Functional studies often show increased calcium sensitivity, but experimental systems and phosphorylation conditions influence the result. In vitro function strengthens classification only when the model is validated and the finding agrees with segregation and independent clinical observations.

For MYH7, position in the motor domain or tail and the variant mechanism influence phenotype, but no map can predict RCM for every substitution. MYH7 variants may cause HCM, DCM, noncompaction or myopathy; a rare variant in a restrictive patient therefore requires specific evidence. The variant-phenotype relationship takes precedence over the generic reputation of the gene.

FLNC missense variants that promote aggregation have been described in restrictive families, whereas many truncating variants cause loss of function and a dilated-arrhythmogenic phenotype. Overlap exists and the rule is not absolute, but variant type modifies clinical and laboratory assessment. The direction of mechanism prevents all FLNC findings from being considered equivalent.

In desminopathies, atrioventricular block and arrhythmias may precede cardiomyopathy or weakness. Variants in the rod domain disrupt filament assembly, while others promote aggregates; dominant inheritance is common but recessive forms can be severe and early. The conduction-muscle sequence varies and requires joint cardiologic and neurologic surveillance even in the apparently single-organ relative.

A variant may be penetrant in some families and less so in others because of background, environment or selection bias. Tertiary-center cohorts often overestimate severity compared with carriers identified by cascade testing, and RCM numbers remain small. Quantitative uncertainty should accompany any risk percentage, distinguishing events in the proband from penetrance in relatives.

Phenocopies, double variants and unexpected findings

A family may contain two different diseases, especially when common heart diseases and longevity overlap. An older person with wild-type ATTR and a child with sarcomeric RCM do not demonstrate transmission of amyloidosis; similarly, hypertension or valve disease may explain a borderline relative. Verified clinical segregation requires every individual to be phenotyped and not counted as affected solely on the basis of a reported diagnosis.

Double pathogenic variants are rare but may modify severity or produce complex phenotypes. Their presence does not justify mechanically adding risks and should be distinguished from a second VUS, an event far more common with broad panels. Multilocus complexity is evaluated through segregation and specific data, avoiding ad hoc explanations for every familial difference.

A secondary finding in an actionable gene may emerge during exome or genome analysis but does not necessarily belong to the proband's RCM. Consent, the list of secondary genes and the confirmation pathway should be defined before analysis. Management of secondary findings separates useful prevention from etiologic confusion and ensures that a result is returned with appropriate counseling.

Consanguinity, multiple affected siblings with healthy parents or a syndromic phenotype raise consideration of recessive inheritance. The dominant model should not be imposed simply because it is most common; biallelic variants in DES or other genes can cause early onset and extracardiac manifestations. Mendelian compatibility guides filtering and interpretation and may completely change risk for siblings and children.

Somatic or germline mosaicism sometimes explains an apparently de novo variant and recurrence among siblings. Sensitivity of peripheral blood is not absolute and low levels may require deep methods or another tissue in selected cases. Mosaicism counseling avoids communicating a zero recurrence risk to parents when biology does not support it.

Ethics, reproduction and risk communication

Predictive testing in a competent adult requires a voluntary choice and the option to defer. Some people want to know their risk to plan follow-up and family, whereas others prefer not to know until there is an immediate benefit; both decisions require respect. Informed autonomy is not a signed form but an understanding of penetrance, uncertainty and family consequences.

In minors, testing is justified when the result changes surveillance or treatment during childhood. If familial disease begins only late and there is no pediatric intervention, deferral preserves the future right to choose; RCM with childhood onset, however, often represents the opposite situation. Pediatric proportionality uses the concrete gene and family, not the same rule for all cardiomyopathies.

Prenatal diagnosis and preimplantation genetic testing are technically possible when the causal variant is certain, but penetrance and expressivity make severity unpredictable. Counseling presents alternatives, limitations, timing and probabilities without steering toward a morally preferred choice. Reproductive nondirectiveness is particularly important in a disease that may range from severe childhood onset to incomplete penetrance.

Communication to relatives raises shared responsibilities and privacy issues. The team may provide a family letter explaining risk without disclosing unnecessary details, while the proband decides how to convey it according to law. Cascade communication increases access to screening and reduces the burden of having to explain complex genetic terms alone.

The genetic result is reinterpreted as evidence changes, but the family should know who maintains contact and how updates will be received. Laboratory, clinical center and patient share this responsibility; a static report stored for decades loses value. Result governance transforms genetics from a one-time event into longitudinal clinical information.

Serial data and transition between phases

A carrier moves from genotype-positive/phenotype-negative status to manifest disease when consistent and reproducible abnormalities appear, not at the first borderline value. The threshold combines ECG, atria, diastolic function, tissue, arrhythmias and symptoms and may be discussed by a team. Phenotypic conversion should be documented because it affects insurance, activity, therapy and personal perception.

Progression is not always linear: volume and rhythm modify diastolic parameters, while magnetic resonance may reveal stable fibrosis. Follow-up therefore compares conditions and methods and distinguishes fluctuation from trend. Longitudinal consistency avoids medicalizing a carrier because of measurement noise or missing slow atrial growth because every report is read in isolation.

When the phenotype emerges, management moves from screening to complete staging, including pressures, arrhythmias and advanced assessment. Follow-up becomes more frequent and the family receives an updated explanation of observed penetrance. The care transition does not consist merely of adding a drug, but of changing objectives from early recognition to prevention of complications.

Family registries and rare-disease networks make it possible to aggregate data on genes with few cases and recalibrate risk and indications. Participation and data sharing require consent, security and return of results. Collective knowledge is particularly important in RCM, where no single center observes enough patients to define the natural history of every variant.

Even with a molecular diagnosis, care remains person-centered. The gene does not measure aspirations, family burden, willingness to accept a device or reproductive preferences and does not replace conversation. Precision medicine is complete only when biologic information is applied to individual goals and updated with clinical evolution.